TWI567061B - 用於治療成癮之化合物 - Google Patents

用於治療成癮之化合物 Download PDF

Info

Publication number
TWI567061B
TWI567061B TW101122794A TW101122794A TWI567061B TW I567061 B TWI567061 B TW I567061B TW 101122794 A TW101122794 A TW 101122794A TW 101122794 A TW101122794 A TW 101122794A TW I567061 B TWI567061 B TW I567061B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
hydrogen
optionally substituted
compound
Prior art date
Application number
TW101122794A
Other languages
English (en)
Chinese (zh)
Other versions
TW201307288A (zh
Inventor
卡莉娜 坎妮沙羅
麥可 葛羅
尤安 桂烈羅
陸亞凡
羅伯特 史脆克利
香德拉塞卡 凡卡塔拉馬尼
傑夫 贊布洛奇
Original Assignee
吉李德科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吉李德科學股份有限公司 filed Critical 吉李德科學股份有限公司
Publication of TW201307288A publication Critical patent/TW201307288A/zh
Application granted granted Critical
Publication of TWI567061B publication Critical patent/TWI567061B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW101122794A 2011-07-01 2012-06-26 用於治療成癮之化合物 TWI567061B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503923P 2011-07-01 2011-07-01

Publications (2)

Publication Number Publication Date
TW201307288A TW201307288A (zh) 2013-02-16
TWI567061B true TWI567061B (zh) 2017-01-21

Family

ID=46513858

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101122794A TWI567061B (zh) 2011-07-01 2012-06-26 用於治療成癮之化合物

Country Status (32)

Country Link
US (6) US8558001B2 (OSRAM)
EP (2) EP2993170B1 (OSRAM)
JP (1) JP5943998B2 (OSRAM)
KR (2) KR101664915B1 (OSRAM)
CN (1) CN103635460B (OSRAM)
AP (1) AP3544A (OSRAM)
AR (1) AR086792A1 (OSRAM)
AU (1) AU2012279332B2 (OSRAM)
BR (1) BR112014000033A2 (OSRAM)
CA (1) CA2840763C (OSRAM)
CL (1) CL2013003597A1 (OSRAM)
CO (1) CO6821964A2 (OSRAM)
CR (1) CR20130659A (OSRAM)
DK (1) DK2993170T3 (OSRAM)
EA (1) EA025573B1 (OSRAM)
EC (1) ECSP13013087A (OSRAM)
ES (2) ES2656716T3 (OSRAM)
IL (1) IL230657B (OSRAM)
MA (1) MA35404B1 (OSRAM)
MD (1) MD4436B1 (OSRAM)
MX (1) MX337611B (OSRAM)
PE (1) PE20141067A1 (OSRAM)
PH (1) PH12013502674A1 (OSRAM)
PL (1) PL2726460T3 (OSRAM)
PT (1) PT2726460E (OSRAM)
SG (1) SG10201605355RA (OSRAM)
SI (1) SI2726460T1 (OSRAM)
TW (1) TWI567061B (OSRAM)
UA (1) UA109199C2 (OSRAM)
UY (1) UY34165A (OSRAM)
WO (1) WO2013006400A1 (OSRAM)
ZA (1) ZA201308977B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TWI577670B (zh) 2011-05-10 2017-04-11 基利科學股份有限公司 充當離子通道調節劑之稠合雜環化合物
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
US9670162B2 (en) * 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
US9163042B2 (en) * 2013-12-13 2015-10-20 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US10077669B2 (en) 2014-11-26 2018-09-18 United Technologies Corporation Non-metallic engine case inlet compression seal for a gas turbine engine
US10289971B2 (en) 2015-02-13 2019-05-14 Atlassian Pty Ltd Issue and trigger rebalancing in a ranked issue management system
JP7178538B2 (ja) 2016-08-19 2022-11-28 ザ ユニバーシティ オブ ブリストル 化合物
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
JP2020536970A (ja) * 2017-10-16 2020-12-17 アミグダラ ニューロサイエンシス インコーポレイテッド 嗜癖を予防するための組み合わせ療法
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PE20210004A1 (es) 2018-05-14 2021-01-05 Gilead Sciences Inc Inhibidores de mcl-1
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
WO2020023792A1 (en) * 2018-07-27 2020-01-30 Amygdala Neurosciences, Inc. Combination therapy for nicotine addiction
WO2020076974A1 (en) * 2018-10-12 2020-04-16 Amygdala Neurosciences, Inc. Addiction treatment of an alcohol-consuming patient population
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062308A1 (en) * 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
CA2334830A1 (en) * 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
JP2006501180A (ja) * 2002-06-27 2006-01-12 ジ エンドウメント フォア リサーチ イン ヒューマン バイオロジー インコーポレイテッド Ａｌｄｈの阻害に有効な化合物
JP2004182657A (ja) * 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US20080207610A1 (en) 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
WO2008014497A2 (en) 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
US8158810B2 (en) 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
CN101925590A (zh) 2008-01-24 2010-12-22 吉利德帕洛阿尔托股份有限公司 治疗成瘾的aldh-2抑制剂
US8138178B2 (en) 2008-05-01 2012-03-20 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TWI567061B (zh) * 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062308A1 (en) * 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof

Also Published As

Publication number Publication date
DK2993170T3 (da) 2018-01-29
MD4436B1 (ro) 2016-09-30
EP2993170A1 (en) 2016-03-09
AR086792A1 (es) 2014-01-22
MX2013014938A (es) 2014-04-30
EA025573B1 (ru) 2017-01-30
ES2656716T3 (es) 2018-02-28
PE20141067A1 (es) 2014-09-05
PT2726460E (pt) 2015-12-07
US20150250805A1 (en) 2015-09-10
WO2013006400A1 (en) 2013-01-10
JP2014520809A (ja) 2014-08-25
KR20160106207A (ko) 2016-09-09
IL230657B (en) 2018-02-28
HK1197236A1 (en) 2015-01-09
EP2726460B1 (en) 2015-09-23
EP2726460A1 (en) 2014-05-07
CA2840763C (en) 2019-09-10
CR20130659A (es) 2014-02-18
TW201307288A (zh) 2013-02-16
US20130005689A1 (en) 2013-01-03
PH12013502674A1 (en) 2014-02-10
US10507215B2 (en) 2019-12-17
US20170266210A1 (en) 2017-09-21
SG10201605355RA (en) 2016-08-30
UA109199C2 (uk) 2015-07-27
ECSP13013087A (es) 2014-01-31
CN103635460B (zh) 2016-03-16
PL2726460T3 (pl) 2016-03-31
MD20140009A2 (ro) 2014-06-30
KR20140042884A (ko) 2014-04-07
MA35404B1 (fr) 2014-09-01
US9000015B2 (en) 2015-04-07
CA2840763A1 (en) 2013-01-10
UY34165A (es) 2013-01-31
AP3544A (en) 2016-01-14
JP5943998B2 (ja) 2016-07-05
AU2012279332A1 (en) 2013-04-04
CO6821964A2 (es) 2013-12-31
EA201391635A1 (ru) 2014-04-30
AU2012279332B2 (en) 2015-02-05
IL230657A0 (en) 2014-03-31
US9987295B2 (en) 2018-06-05
CL2013003597A1 (es) 2014-06-13
MX337611B (es) 2016-03-10
KR101664915B1 (ko) 2016-10-11
ES2553829T3 (es) 2015-12-14
BR112014000033A2 (pt) 2019-06-18
US8558001B2 (en) 2013-10-15
US20130203704A1 (en) 2013-08-08
NZ618537A (en) 2016-03-31
EP2993170B1 (en) 2017-10-25
US20180338989A1 (en) 2018-11-29
US8575353B2 (en) 2013-11-05
AP2013007282A0 (en) 2013-11-30
SI2726460T1 (sl) 2015-11-30
ZA201308977B (en) 2014-08-27
US20140051668A1 (en) 2014-02-20
CN103635460A (zh) 2014-03-12
HK1217487A1 (en) 2017-01-13
US9610299B2 (en) 2017-04-04

Similar Documents

Publication Publication Date Title
TWI567061B (zh) 用於治療成癮之化合物
CA2682207A1 (en) Quinazolinone derivatives as aldh-2 inhibitors
TWI468403B (zh) 用於治療成癮之ａｌｄｈ－２抑制劑
JP2020536970A (ja) 嗜癖を予防するための組み合わせ療法
HK1217487B (en) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction
AU2015202264A1 (en) Compounds for the treatment of addiction
NZ618537B2 (en) Mitochondrial aldehyde dehydrogenase (ALDH-2) inhibitors
AU2016244324A1 (en) Compounds for the treatment of addiction
OA16801A (en) Compounds for the treatment of addiction.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees